Viridian Shares New 52-Week Phase III Trial Data for Active TED
New THRIVE trial data highlight long-term proptosis response with veligrotug in thyroid eye disease patients. Fresh long-term data is showing…
The Next-Gen Arsenal of Genomic Tools for IRDs and Other Eye Diseases Lighting Up ARVO 2025
Innovative genomic techniques on display at ARVO 2025 could slam the door shut on some of the biggest challenges in…
latest posts
